Published Date: 2020-02-19 | Pages: 112 | Tables: 142 | Report ID: 7419 | Industry: Life Science | Format :
Need to Bring down Number of New Cancer Cases Likely to Propel Demand
The global paclitaxel market is anticipated to benefit from the increasing number of cancer research studies, need for novel anti-cancer drugs, and high demand for targeted, personalized cancer treatments. Growing focus on the development of oral paclitaxel cancer treatments is expected to remarkably contribute to the growth of the global paclitaxel market. Late in 2019, Athenex announced that oral paclitaxel along with encequidar showed much better survival and response rates in the treatment of metastatic breast cancer compared to IV paclitaxel, as per the results from a phase III clinical trial.
Increasing efforts from governments, international cancer research institutions, and global healthcare organizations to decrease the incidence of different cancer types are anticipated to set the tone for strong growth of the global paclitaxel market.
● Natural Paclitaxel API
● Semi-synthetic Paclitaxel API
● Ovarian Cancer
● Cervical Cancer
● Breast Cancer
The demand for natural paclitaxel API is expected to significantly increase in the coming years. The rising preference for natural ingredients to manufacture pharmaceutical products could strengthen the growth of the natural paclitaxel API segment of the global paclitaxel market. Moreover, natural paclitaxel API is considered to be ideal, safe, and effective for use in cancer treatment. In addition, it finds application in the production of new taxane anticancer derivatives. The use of paclitaxel is anticipated to increase in ovarian cancer treatment. According to the American Cancer Society, there could be more than 21,000 new ovarian cancer cases in the US in 2020.
· North America is predicted to gain a large share of the global paclitaxel market due to the high prevalence of cancer. In 2020, there could be over 1.8 million new cancer cases in the US, as per the statistics of the American Cancer Society. Furthermore, there could be over 600,000 cancer deaths in the US in the same year. Increase in the research and development of new cancer drugs and formulations in countries such as the US is anticipated to further add to the growth of the North America paclitaxel market.
Manufacturers to Invest in Research and Development of New Paclitaxel Injectable FDFs
Key players operating in the global paclitaxel market are Phyton Biotech, Jiangsu Yew Biotechnology, ScinoPharm, Hainan Yew Pharm, Novasep, Yunnan Hande, Samyang, Southpharma, Polymed Therapeutics, TAPI (Teva), Huiang Biopharma, and Fresenius Kabi. Players are expected to show high interest in paclitaxel injectable drugs because of their high use as an anti-cancer chemotherapy drug. In April 2019, Phyton Biotech and AqVida received approval for the latter’s paclitaxel injectable finished dosage formulation from the European Directorate of Quality Medicines.
Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.
QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.
We are committed to delivering the best solutions and we offer a 24*7 helpline.
We promise superior quality of authenticated data.
We offer help and advice across varying time zones.
We boast a strong team of experienced analysts.
We have an exhaustive repository of published reports.
For Enquiry : firstname.lastname@example.org
We have the fastest report delivery service with excellent after-sales support
We provide a comprehensive and in-depth analysis in every report that we sell
We own large database which will help our clients to get customized and syndicated research reports
To offer you accurate data, our seasoned analysts will be available to assist you
NOTE - The analysis, thoughts, views, facts, and opinions expressed in this report are of the respective research analysts. QYR Consulting does not necessarily endorse it or it is also not essentially formal views of QYR Consulting.